I’m currently arguing a statistical plan for a neurostim phase two clinical trial IDE submission with the FDA. We got some borderline reckless comments back that are massively out of line with correspondence on previous pivotal submissions. It’s starting to look like some of the reviewers are taking on work outside the scope of their expertise. Really disappointing to see, especially with the new more streamlined MDR reqs coming out of the EU.